Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Rectal Cancer
Status:
Unknown status
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This is a nonrandomised pilot trial to establish the role of intravenous cetuximab when added
to a schedule of capecitabine plus pelvic radiation in patients who have locally advanced
primary resectable rectal cancers.